Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Is AXSM or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-49.88%	-283.22%	-33.06%
Jazz Pharmaceuticals	-9.91%	5.02%	1.73%

Which has more volatility & risk, AXSM or JAZZ?

Axsome Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

Does the media refer more to AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Axsome Therapeutics. MarketBeat recorded 16 mentions for Jazz Pharmaceuticals and 13 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.38 beat Jazz Pharmaceuticals' score of 0.99 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in AXSM or JAZZ?

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend AXSM or JAZZ?

Axsome Therapeutics presently has a consensus price target of $178.00, indicating a potential upside of 53.25%. Jazz Pharmaceuticals has a consensus price target of $181.43, indicating a potential upside of 45.73%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87

Which has better valuation & earnings, AXSM or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$495.03M	11.71	-$287.22M	-$5.07	-22.91
Jazz Pharmaceuticals	$4.07B	1.86	$560.12M	-$6.73	-18.50

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.